Aquestive rugi bersih GAAP Q2 FY26 melebar jadi USD 22,9 juta; revenue naik 38% jadi USD 13,8 juta
Reuters2026/08/11 20:02- Aquestive Therapeutics membukukan revenue kuartal II 2026 naik 38% menjadi $13,8 juta.
- Rugi bersih GAAP melebar menjadi $22,9 juta; rugi per saham GAAP memburuk menjadi $0,18.
- Adjusted EBITDA loss non-GAAP menyempit menjadi $5,2 juta dari $9,3 juta pada kuartal II 2025.
- Kas dan setara kas per 30 Juni 2026 turun menjadi $98,5 juta.
- Untuk Anaphylm, studi human factors dan PK selesai; tetap menargetkan resubmisi NDA pada kuartal III 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
